Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

BACKGROUND: The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib. METHODS: Relapsed...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seok Jin, Yoon, Dok Hyun, Kang, Hye Jin, Hong, Jung Yong, Lee, Ho Sup, Oh, Sung Yong, Shin, Ho-Jin, Kong, Jee Hyun, Yi, Jun Ho, Sakamoto, Kana, Ko, Young Hyeh, Huh, Jooryung, Lee, Seung-Sook, Takeuchi, Kengo, Shin, Dong-Yeop, Suh, Cheolwon, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842512/
https://www.ncbi.nlm.nih.gov/pubmed/31707975
http://dx.doi.org/10.1186/s12885-019-6303-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842512/
https://www.ncbi.nlm.nih.gov/pubmed/31707975
http://dx.doi.org/10.1186/s12885-019-6303-z

Ejemplares similares